| Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation (NCT00658411) | Dana-Farber Cancer Institute | 2008-08-01 |
| Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer (NCT00658697) | Dana-Farber Cancer Institute | 2008-06-01 |
| Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma (NCT00684411) | Dana-Farber Cancer Institute | 2008-06-01 |
| RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors (NCT00576680) | Dana-Farber Cancer Institute | 2008-05-01 |
| Lung Cancer Symptom Assessment and Management Intervention (NCT00852462) | Dana-Farber Cancer Institute | 2008-05-01 |
| Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer (NCT00611858) | Dana-Farber Cancer Institute | 2008-05-01 |
| Observational Study of Iron Overload in Stem Cell Transplantation (NCT00954720) | Dana-Farber Cancer Institute | 2008-03-01 |
| A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors (NCT00633958) | Dana-Farber Cancer Institute | 2008-03-01 |
| RAD001 and Bicalutamide for Androgen Independent Prostate Cancer (NCT00630344) | Dana-Farber Cancer Institute | 2008-02-01 |
| Hypertension in Breast Cancer Patients Receiving Bevacizumab (NCT00674011) | Dana-Farber Cancer Institute | 2008-01-01 |
| Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies (NCT00675831) | Dana-Farber Cancer Institute | 2007-12-01 |
| Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck (NCT00570674) | Dana-Farber Cancer Institute | 2007-11-01 |
| Simvastatin in Waldenstrom's Macroglobulinemia (NCT00575965) | Dana-Farber Cancer Institute | 2007-11-01 |
| Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL (NCT00543114) | Dana-Farber Cancer Institute | 2007-10-01 |
| The Active After Cancer Trial (AACT) (NCT00548236) | Dana-Farber Cancer Institute | 2007-10-01 |
| Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer (NCT00542451) | Dana-Farber Cancer Institute | 2007-10-01 |
| Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation (NCT00548717) | Dana-Farber Cancer Institute | 2007-10-01 |
| Vitamin D for Chemoprevention (NCT00585637) | Dana-Farber Cancer Institute | 2007-10-01 |
| Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors (NCT00520013) | Dana-Farber Cancer Institute | 2007-08-01 |
| Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma (NCT00512889) | Dana-Farber Cancer Institute | 2007-08-01 |
| SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma (NCT00577382) | Dana-Farber Cancer Institute | 2007-08-01 |
| Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease (NCT00529035) | Dana-Farber Cancer Institute | 2007-08-01 |
| ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer (NCT00496665) | Dana-Farber Cancer Institute | 2007-07-01 |
| Campath in Chronic GVHD (NCT00495755) | Dana-Farber Cancer Institute | 2007-07-01 |
| Rapamycin in Relapsed Acute Lymphoblastic Leukemia (NCT00874562) | Dana-Farber Cancer Institute | 2007-07-01 |
| Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (NCT00487305) | Dana-Farber Cancer Institute | 2007-06-01 |
| Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials (NCT00487513) | Dana-Farber Cancer Institute | 2007-06-01 |
| Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers (NCT00545792) | Dana-Farber Cancer Institute | 2007-05-01 |
| Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma (NCT00483262) | Dana-Farber Cancer Institute | 2007-05-01 |
| ALL Adult Consortium Trial: Adult ALL Trial (NCT00476190) | Dana-Farber Cancer Institute | 2007-04-01 |
| Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck (NCT00459043) | Dana-Farber Cancer Institute | 2007-03-01 |
| Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (NCT00431210) | Dana-Farber Cancer Institute | 2007-02-01 |
| Personal Patient Profile Prostate (P4) Randomized, Multisite Trial (NCT00692653) | Dana-Farber Cancer Institute | 2007-02-01 |
| Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination (NCT00442130) | Dana-Farber Cancer Institute | 2007-02-01 |
| ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer (NCT00436072) | Dana-Farber Cancer Institute | 2007-02-01 |
| Skin Cancer Screening and Education at Beaches (NCT00894855) | Dana-Farber Cancer Institute | 2007-01-01 |
| C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NCT00402545) | Dana-Farber Cancer Institute | 2007-01-01 |
| RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer (NCT00409292) | Dana-Farber Cancer Institute | 2007-01-01 |
| Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar (NCT00476476) | Dana-Farber Cancer Institute | 2006-12-01 |
| Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation (NCT00428233) | Dana-Farber Cancer Institute | 2006-11-01 |
| The Young Women's Breast Cancer Study (NCT01468246) | Dana-Farber Cancer Institute | 2006-11-01 |
| Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease (NCT00601146) | Dana-Farber Cancer Institute | 2006-11-01 |
| Melatonin Versus Placebo in Breast Cancer (NCT01805089) | Dana-Farber Cancer Institute | 2006-10-01 |
| Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma (NCT00418093) | Dana-Farber Cancer Institute | 2006-09-01 |
| Rituximab for Prevention of Chronic GVHD (NCT00379587) | Dana-Farber Cancer Institute | 2006-09-01 |
| Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia (NCT00422656) | Dana-Farber Cancer Institute | 2006-09-01 |
| Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC (NCT00880334) | Dana-Farber Cancer Institute | 2006-09-01 |
| Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma (NCT00378105) | Dana-Farber Cancer Institute | 2006-09-01 |
| Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer (NCT00394433) | Dana-Farber Cancer Institute | 2006-09-01 |
| Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) (NCT00422799) | Dana-Farber Cancer Institute | 2006-08-30 |
| Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma (NCT00378209) | Dana-Farber Cancer Institute | 2006-08-01 |
| Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus (NCT00476086) | Dana-Farber Cancer Institute | 2006-08-01 |
| Exercise Intervention in Women With Metastatic Breast Cancer (NCT00405782) | Dana-Farber Cancer Institute | 2006-08-01 |
| Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation (NCT00369226) | Dana-Farber Cancer Institute | 2006-08-01 |
| Ph II CHOP+Velcade in Mediastinal LBCL (NCT00361621) | Dana-Farber Cancer Institute | 2006-07-01 |
| Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (NCT00424515) | Dana-Farber Cancer Institute | 2006-07-01 |
| Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation (NCT00355407) | Dana-Farber Cancer Institute | 2006-06-01 |
| Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer (NCT00578149) | Dana-Farber Cancer Institute | 2006-05-01 |
| A Pilot Weight Control Intervention at HPHC (NCT00644202) | Dana-Farber Cancer Institute | 2006-05-01 |
| Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL (NCT00330252) | Dana-Farber Cancer Institute | 2006-05-01 |
| Trial of PTK787/ZK 222584 Plus Paclitaxel (NCT00358163) | Dana-Farber Cancer Institute | 2006-04-26 |
| Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer (NCT00322881) | Dana-Farber Cancer Institute | 2006-04-01 |
| Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function (NCT00525460) | Dana-Farber Cancer Institute | 2006-04-01 |
| Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients (NCT00317603) | Dana-Farber Cancer Institute | 2006-01-01 |
| Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation (NCT00282282) | Dana-Farber Cancer Institute | 2006-01-01 |
| Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer (NCT00880464) | Dana-Farber Cancer Institute | 2006-01-01 |
| RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS (NCT00126672) | Dana-Farber Cancer Institute | 2005-12-20 |
| Pemetrexed in Patients With Advanced Neuroendocrine Tumors (NCT00424723) | Dana-Farber Cancer Institute | 2005-12-01 |
| The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer (NCT00459186) | Dana-Farber Cancer Institute | 2005-11-01 |
| Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer (NCT00280930) | Dana-Farber Cancer Institute | 2005-10-01 |
| Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia (NCT00250926) | Dana-Farber Cancer Institute | 2005-10-01 |
| Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme (NCT00165477) | Dana-Farber Cancer Institute | 2005-09-01 |
| Sildenafil Citrate in Waldenstrom's Macroglobulinemia (NCT00165295) | Dana-Farber Cancer Institute | 2005-09-01 |
| A Web Site and Print Materials Intervention for Smoking Intervention for Childhood and Young Adult Cancer Survivors (NCT00588107) | Dana-Farber Cancer Institute | 2005-09-01 |
| Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients (NCT00268918) | Dana-Farber Cancer Institute | 2005-09-01 |
| Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer (NCT00230542) | Dana-Farber Cancer Institute | 2005-09-01 |
| CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation (NCT00333190) | Dana-Farber Cancer Institute | 2005-09-01 |
| Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia (NCT00301093) | Dana-Farber Cancer Institute | 2005-09-01 |
| Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (NCT00130702) | Dana-Farber Cancer Institute | 2005-08-01 |
| Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma (NCT00126191) | Dana-Farber Cancer Institute | 2005-07-01 |
| Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer (NCT00130689) | Dana-Farber Cancer Institute | 2005-07-01 |
| Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer (NCT00165568) | Dana-Farber Cancer Institute | 2005-07-01 |
| Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer (NCT00139191) | Dana-Farber Cancer Institute | 2005-07-01 |
| Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease (NCT00165412) | Dana-Farber Cancer Institute | 2005-07-01 |
| Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant (NCT00376480) | Dana-Farber Cancer Institute | 2005-06-01 |
| Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer (NCT00116142) | Dana-Farber Cancer Institute | 2005-06-01 |
| Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer (NCT00165334) | Dana-Farber Cancer Institute | 2005-06-01 |
| Computerized Assessment for Patients With Cancer (NCT00194493) | Dana-Farber Cancer Institute | 2005-04-01 |
| Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients (NCT00139204) | Dana-Farber Cancer Institute | 2005-04-01 |
| 05-001: Treatment of Acute Lymphoblastic Leukemia in Children (NCT00400946) | Dana-Farber Cancer Institute | 2005-04-01 |
| Mifepristone (RU-486) in Androgen Independent Prostate Cancer (NCT00140478) | Dana-Farber Cancer Institute | 2005-02-01 |
| Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma (NCT00119730) | Dana-Farber Cancer Institute | 2005-02-01 |
| Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma (NCT00258687) | Dana-Farber Cancer Institute | 2005-01-01 |
| Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer (NCT00357500) | Dana-Farber Cancer Institute | 2005-01-01 |
| Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer (NCT00116506) | Dana-Farber Cancer Institute | 2005-01-01 |
| The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology (NCT01838564) | Dana-Farber Cancer Institute | 2004-11-01 |
| Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors (NCT00137774) | Dana-Farber Cancer Institute | 2004-11-01 |
| Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy (NCT00146536) | Dana-Farber Cancer Institute | 2004-11-01 |
| Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer (NCT00137761) | Dana-Farber Cancer Institute | 2004-10-01 |
| Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer (NCT00148707) | Dana-Farber Cancer Institute | 2004-10-01 |